Company: STAA
Filing Date: 2025-10-07
Form Type: PX14A6G
Source: 0001193125-25-232531
Chunk: 0

Company: STAAR SURGICAL CO
Filing Date: 2025-10-07
Form: PX14A6G
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Submitted Pursuant to Rule 14a-6(g) (Amendment No. _)

| 1. | Name of the Registrant: |

STAAR SURGICAL CO

| 2. | Name of Person Relying on Exemption: |

Yunqi Capital Limited

| 3. | Address of Person Relying on Exemption: |

Unit 3703, 37/F, AIA Tower, 183 Electric Road, North Point, Hong Kong

| 4. | Written Materials. The following written material is attached hereto: |

Press release, dated October 7, 2025, attached hereto as Exhibit 1. * * * Written material is submitted pursuant to Rule 14a-6(g)(1)promulgated under the Securities Exchange Act of 1934, as amended. This is not a solicitation of authority to vote any proxy. Yunqi Capital Limited (together with its affiliates, “Yunqi Capital”) is not asking for your proxy card and will not accept proxy cards if sent. The cost of this filing is being borne entirely by Yunqi Capital. PLEASE NOTE: Yunqi Capital is not asking for your proxy card and cannot accept your proxy card. Please DO NOT send us your proxy card. (Written material follows on next page)

Exhibit 1

Yunqi Capital, One of STAAR Surgical Company’s Largest Shareholders, Reiterates Its

Opposition to the Proposed Merger with Alcon

STAAR Continues to Significantly Underestimate the Strength of the Business and Future

Prospects and Misrepresent Its Performance, Competitive Position, and Market Penetration

Incentives for STAAR’s CEO Are Not Aligned with Shareholders

Shareholders Should Preserve the Value of Their Investment and Vote Against the Proposed Merger

HONG KONG, October 7, 2025 – Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment
management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ:STAA), today released the following open letter reiterating its opposition to the proposed sale to Alcon Inc.
(SIX/NYSE:ALC) on the terms announced on August 5, 2025.

October